NO20045517L - Ny kombinasjon - Google Patents

Ny kombinasjon

Info

Publication number
NO20045517L
NO20045517L NO20045517A NO20045517A NO20045517L NO 20045517 L NO20045517 L NO 20045517L NO 20045517 A NO20045517 A NO 20045517A NO 20045517 A NO20045517 A NO 20045517A NO 20045517 L NO20045517 L NO 20045517L
Authority
NO
Norway
Prior art keywords
inhibitor
new combination
aee
pde5
cgmp
Prior art date
Application number
NO20045517A
Other languages
English (en)
Norwegian (no)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211919A external-priority patent/GB0211919D0/en
Priority claimed from GB0229784A external-priority patent/GB0229784D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20045517L publication Critical patent/NO20045517L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20045517A 2002-05-23 2004-12-17 Ny kombinasjon NO20045517L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0211919A GB0211919D0 (en) 2002-05-23 2002-05-23 Novel combination
GB0229784A GB0229784D0 (en) 2002-12-20 2002-12-20 Novel combination
PCT/IB2003/001889 WO2003099194A2 (en) 2002-05-23 2003-05-09 Pharmaceutical combination of pde5 inhibitors with ace inhibitors

Publications (1)

Publication Number Publication Date
NO20045517L true NO20045517L (no) 2004-12-17

Family

ID=29585817

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045517A NO20045517L (no) 2002-05-23 2004-12-17 Ny kombinasjon

Country Status (18)

Country Link
EP (1) EP1506015A2 (https=)
JP (1) JP2005529927A (https=)
KR (1) KR20050004195A (https=)
CN (1) CN1655820A (https=)
AR (1) AR040090A1 (https=)
AU (1) AU2003223071A1 (https=)
BR (1) BR0311191A (https=)
CA (1) CA2485984A1 (https=)
IL (1) IL164975A0 (https=)
MX (1) MXPA04010951A (https=)
NO (1) NO20045517L (https=)
PA (1) PA8574201A1 (https=)
PE (1) PE20040514A1 (https=)
PL (1) PL374198A1 (https=)
RU (1) RU2004133973A (https=)
TW (1) TW200407153A (https=)
UY (1) UY27816A1 (https=)
WO (1) WO2003099194A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
JP2010501577A (ja) 2006-08-24 2010-01-21 サーフェイス ロジックス，インコーポレイティド 薬物動態が改善された化合物
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP3167876B1 (en) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
EP3021832B9 (en) 2013-07-19 2023-03-15 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CA2930033C (en) 2013-12-04 2022-12-13 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6362178B1 (en) * 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AP2002002455A0 (en) * 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.

Also Published As

Publication number Publication date
PL374198A1 (en) 2005-10-03
CA2485984A1 (en) 2003-12-04
MXPA04010951A (es) 2005-06-08
JP2005529927A (ja) 2005-10-06
AU2003223071A1 (en) 2003-12-12
PE20040514A1 (es) 2004-08-24
IL164975A0 (en) 2005-12-18
KR20050004195A (ko) 2005-01-12
UY27816A1 (es) 2003-12-31
BR0311191A (pt) 2005-03-01
PA8574201A1 (es) 2003-12-19
WO2003099194A2 (en) 2003-12-04
CN1655820A (zh) 2005-08-17
WO2003099194A3 (en) 2004-06-03
TW200407153A (en) 2004-05-16
AR040090A1 (es) 2005-03-16
RU2004133973A (ru) 2005-09-10
EP1506015A2 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
NO20045517L (no) Ny kombinasjon
HN2003000227A (es) Inhibidores de quinasas
DK1483265T3 (da) Purinderivater som kinaseinhibitorer
NO20053115L (no) Fremgangsmate for fremstilling av 2'-forgrenede nukleosider.
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
HUP0104131A2 (hu) Aminnal reakcióra képes egy vagy több aktív összetevőt tartalmazó készítmények
SE0203752D0 (sv) New compounds
ATE414699T1 (de) Inhibitoren von tyrosinkinasen
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
MXPA03007049A (es) Inhibidores heterociclicos de erk2 y usos de los mismos.
DE69811645D1 (de) Phtalazinonen
EP1490373A4 (en) Inhibitors of nucleoside phosphorylases and nucleosideases
MXPA05006629A (es) Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador.
MXPA04011951A (es) Inhibidores de peptido desformilasa.
DE602004009824D1 (de) Analyse von massenspektraldaten in den ruhigen gebieten
ATE390425T1 (de) Xanthin-phosphodiesterase-v-hemmer polymorphe
NO20050400L (no) Nytt kombinasjonspreparat
EP1513402A4 (en) IMPROVED INHIBITORS OF ADP-RIBOSYL TRANSFERASES, CYCLASES, AND HYDROLASES
EP1570847A4 (en) PHOSPHODIESTERASE 10A HEMMER
NO20043173L (no) Benzotiazol- og benzoksazol-4,7-dionderivater og deres anvendelse som CDC25-fosfataseinhibitorer
SE0302361D0 (sv) Inhibering av upptagning av monoamin
TW200509911A (en) Novel combination
DOP2003000645A (es) Nueva combinacion

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application